CN114539193A - 一种盐酸胺碘酮中间体的制备方法 - Google Patents
一种盐酸胺碘酮中间体的制备方法 Download PDFInfo
- Publication number
- CN114539193A CN114539193A CN202210065051.7A CN202210065051A CN114539193A CN 114539193 A CN114539193 A CN 114539193A CN 202210065051 A CN202210065051 A CN 202210065051A CN 114539193 A CN114539193 A CN 114539193A
- Authority
- CN
- China
- Prior art keywords
- reaction
- butylbenzofuran
- formylphenoxy
- preparation
- hexanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 66
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 title abstract description 13
- 229960003234 amiodarone hydrochloride Drugs 0.000 title abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 95
- OVJKFJDEVKABNF-UHFFFAOYSA-N 2-butyl-1-benzofuran Chemical compound C1=CC=C2OC(CCCC)=CC2=C1 OVJKFJDEVKABNF-UHFFFAOYSA-N 0.000 claims abstract description 66
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract description 64
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims abstract description 48
- BNHZJSWSEINXDJ-UHFFFAOYSA-N 2-(2-formylphenoxy)hexanoic acid Chemical compound CCCCC(C(O)=O)OC1=CC=CC=C1C=O BNHZJSWSEINXDJ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229910000027 potassium carbonate Inorganic materials 0.000 claims abstract description 32
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 94
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 90
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 claims description 69
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 238000005406 washing Methods 0.000 claims description 33
- 238000000605 extraction Methods 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- 239000012044 organic layer Substances 0.000 claims description 27
- 239000002994 raw material Substances 0.000 claims description 26
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 239000010410 layer Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000012295 chemical reaction liquid Substances 0.000 claims description 12
- YGLPDRIMFIXNBI-UHFFFAOYSA-N methyl 2-bromohexanoate Chemical compound CCCCC(Br)C(=O)OC YGLPDRIMFIXNBI-UHFFFAOYSA-N 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 238000007127 saponification reaction Methods 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 9
- 238000004821 distillation Methods 0.000 claims description 9
- 230000020477 pH reduction Effects 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 230000035484 reaction time Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 238000005580 one pot reaction Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 2
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 claims description 2
- 239000002699 waste material Substances 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 77
- 239000012535 impurity Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 230000007062 hydrolysis Effects 0.000 description 12
- 238000006460 hydrolysis reaction Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 238000005070 sampling Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- HMXPIWQSUXBNFU-UHFFFAOYSA-N methyl 2-(2-formylphenoxy)hexanoate Chemical compound CCCCC(C(=O)OC)OC1=CC=CC=C1C=O HMXPIWQSUXBNFU-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AFLGFEMYDUKHRI-UHFFFAOYSA-N C(CCC)C=1OC2=C(C1)C=CC=C2.C(CCC)C=2OC1=C(C2)C=CC=C1 Chemical compound C(CCC)C=1OC2=C(C1)C=CC=C2.C(CCC)C=2OC1=C(C2)C=CC=C1 AFLGFEMYDUKHRI-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- JWSIJFDOWHFZTK-UHFFFAOYSA-N (2-formylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C=O JWSIJFDOWHFZTK-UHFFFAOYSA-N 0.000 description 1
- -1 2-formyl phenoxy Chemical group 0.000 description 1
- CNCBKULTPJTRNN-UHFFFAOYSA-N 5-(1-benzofuran-2-yl)-6-butyl-4-[2-(diethylamino)ethoxy]-3,5-diiodocyclohexa-1,3-diene-1-carbaldehyde hydrochloride Chemical compound CCCCC1C(=CC(=C(C1(C2=CC3=CC=CC=C3O2)I)OCCN(CC)CC)I)C=O.Cl CNCBKULTPJTRNN-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 208000008376 Pre-Excitation Syndromes Diseases 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- NUKZAGXMHTUAFE-UHFFFAOYSA-N hexanoic acid methyl ester Natural products CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 208000008510 paroxysmal tachycardia Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- ZLMJMSJWJFRBEC-OUBTZVSYSA-N potassium-40 Chemical compound [40K] ZLMJMSJWJFRBEC-OUBTZVSYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
编号 | 水解时间 | 2-(2-甲 | 2-(2-甲 | 杂质 |
对比例37 | 1h | 94.48% | 1.31% | 2.34% |
对比例38 | 2h | 95.17% | 0.46% | 3.37% |
对比例39 | 4h | 92.43% | 0.34% | 6.41% |
对比例40 | 7h | 91.62% | 0.21% | 7.51% |
编号 | 调酸pH值 | 收率 | 2-(2-甲 | 水杨 | 2-(2-甲酰 | 杂质 |
对比例41 | 1-2 | 80.34% | 96.76% | 0.02% | 0.07% | 0.40% |
对比例42 | 2-3 | 78.52% | 96.53% | 0.03% | 0.07% | 0.43% |
对比例43 | 3-3.5 | 69.90% | 95.74% | 0.02% | 0.02% | 0.70% |
对比例44 | 4-4.5 | 8.57% | 89.70% | 0.12% | 0.01% | 5.42% |
对比例45 | 5-5.5 | 7.97% | 90.85% | 0.13% | N.D | 5.98% |
对比例46 | 6-6.5 | 2.59% | 84.42% | 0.21% | 0.01% | 11.98% |
编号 | 操作步骤 | 2-(2-甲酰 | 杂质 | 2-丁基苯 |
对比例73 | 反应液 | 1.57% | 1.61% | 94.70% |
对比例74 | 三次萃取后合并有机层 | N.D | 0.43% | 98.24% |
对比例75 | 三次萃取后水层 | 10.79% | 42.63 | 0.07% |
对比例76 | 酸洗后有机层 | 0.04% | 0.36% | 97.49% |
对比例77 | 酸洗后水层 | 8.12% | 11.24% | 3.63% |
对比例78 | 碱洗后有机层 | N.D | 0.09% | 99.03% |
对比例79 | 碱洗后水层 | 64.31% | 0.17% | 0.90% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210065051.7A CN114539193A (zh) | 2022-01-20 | 2022-01-20 | 一种盐酸胺碘酮中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210065051.7A CN114539193A (zh) | 2022-01-20 | 2022-01-20 | 一种盐酸胺碘酮中间体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114539193A true CN114539193A (zh) | 2022-05-27 |
Family
ID=81670842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210065051.7A Pending CN114539193A (zh) | 2022-01-20 | 2022-01-20 | 一种盐酸胺碘酮中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114539193A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115850220A (zh) * | 2022-11-29 | 2023-03-28 | 山东北大高科华泰制药有限公司 | 稳定的盐酸胺碘酮及其制备方法和用途 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002255954A (ja) * | 2001-03-02 | 2002-09-11 | Yoshio Ishino | 2−n−ブチル−5−ニトロベンゾフランの製造方法 |
CN1382133A (zh) * | 1999-10-21 | 2002-11-27 | 罗狄亚化学公司 | 制备苯并呋喃或苯并噻吩类型化合物的方法 |
WO2003084951A1 (en) * | 2002-04-03 | 2003-10-16 | Allergan, Inc. | (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
CN101948455A (zh) * | 2010-10-18 | 2011-01-19 | 山东邹平大展新材料有限公司 | 一种2-正丁基-3-(4-羟基苯甲酰基)-5-硝基苯并呋喃的制备方法 |
CN101948454A (zh) * | 2010-10-11 | 2011-01-19 | 山东邹平大展新材料有限公司 | 一种2-正丁基-5-硝基苯并呋喃的制备方法 |
WO2011099010A1 (en) * | 2010-02-10 | 2011-08-18 | Mapi Pharma Holdings (Cyprus) Limited | Preparation of benzofurans and use thereof as synthetic intermediates |
WO2011121245A1 (fr) * | 2010-04-01 | 2011-10-06 | Sanofi-Aventis | Procédé de préparation de dérivés d'amino-benzofurane |
CN102757444A (zh) * | 2011-04-29 | 2012-10-31 | 江苏先声药物研究有限公司 | 具有一氧化氮供体性质的苯并呋喃类化合物 |
EP2538787A1 (en) * | 2010-02-22 | 2013-01-02 | GlaxoSmithKline LLC | Triazolones as fatty acid synthase inhibitors |
US20130165673A1 (en) * | 2010-03-30 | 2013-06-27 | Sanofi | Method for preparing 3-keto-benzofurane derivatives |
CN104262304A (zh) * | 2014-09-12 | 2015-01-07 | 杨俊� | 一种盐酸胺碘酮的合成方法 |
CN104628686A (zh) * | 2015-01-27 | 2015-05-20 | 南通恒盛精细化工有限公司 | 一种带酰胺侧链的苯并呋喃制备工艺 |
CN107382925A (zh) * | 2017-07-20 | 2017-11-24 | 烟台万润药业有限公司 | 一种盐酸胺碘酮的制备方法 |
CN108675972A (zh) * | 2018-08-01 | 2018-10-19 | 北京嘉林药业股份有限公司 | 一种盐酸胺碘酮中间体2-丁基苯并呋喃的制备方法 |
WO2018210987A1 (en) * | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
WO2018210988A1 (en) * | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
-
2022
- 2022-01-20 CN CN202210065051.7A patent/CN114539193A/zh active Pending
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1382133A (zh) * | 1999-10-21 | 2002-11-27 | 罗狄亚化学公司 | 制备苯并呋喃或苯并噻吩类型化合物的方法 |
JP2002255954A (ja) * | 2001-03-02 | 2002-09-11 | Yoshio Ishino | 2−n−ブチル−5−ニトロベンゾフランの製造方法 |
WO2003084951A1 (en) * | 2002-04-03 | 2003-10-16 | Allergan, Inc. | (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
CN1642944A (zh) * | 2002-04-03 | 2005-07-20 | 阿勒根公司 | 作为激酶抑制剂的(3z)-3-(2,3-二氢-1h-茚-1-叉)-1,3-二氢-2h-吲哚-2-酮 |
WO2011099010A1 (en) * | 2010-02-10 | 2011-08-18 | Mapi Pharma Holdings (Cyprus) Limited | Preparation of benzofurans and use thereof as synthetic intermediates |
EP2538787A1 (en) * | 2010-02-22 | 2013-01-02 | GlaxoSmithKline LLC | Triazolones as fatty acid synthase inhibitors |
US20130165673A1 (en) * | 2010-03-30 | 2013-06-27 | Sanofi | Method for preparing 3-keto-benzofurane derivatives |
WO2011121245A1 (fr) * | 2010-04-01 | 2011-10-06 | Sanofi-Aventis | Procédé de préparation de dérivés d'amino-benzofurane |
CN101948454A (zh) * | 2010-10-11 | 2011-01-19 | 山东邹平大展新材料有限公司 | 一种2-正丁基-5-硝基苯并呋喃的制备方法 |
CN101948455A (zh) * | 2010-10-18 | 2011-01-19 | 山东邹平大展新材料有限公司 | 一种2-正丁基-3-(4-羟基苯甲酰基)-5-硝基苯并呋喃的制备方法 |
CN102757444A (zh) * | 2011-04-29 | 2012-10-31 | 江苏先声药物研究有限公司 | 具有一氧化氮供体性质的苯并呋喃类化合物 |
CN104262304A (zh) * | 2014-09-12 | 2015-01-07 | 杨俊� | 一种盐酸胺碘酮的合成方法 |
CN104628686A (zh) * | 2015-01-27 | 2015-05-20 | 南通恒盛精细化工有限公司 | 一种带酰胺侧链的苯并呋喃制备工艺 |
WO2018210987A1 (en) * | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
WO2018210988A1 (en) * | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
CN107382925A (zh) * | 2017-07-20 | 2017-11-24 | 烟台万润药业有限公司 | 一种盐酸胺碘酮的制备方法 |
CN108675972A (zh) * | 2018-08-01 | 2018-10-19 | 北京嘉林药业股份有限公司 | 一种盐酸胺碘酮中间体2-丁基苯并呋喃的制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115850220A (zh) * | 2022-11-29 | 2023-03-28 | 山东北大高科华泰制药有限公司 | 稳定的盐酸胺碘酮及其制备方法和用途 |
CN115850220B (zh) * | 2022-11-29 | 2024-01-26 | 山东北大高科华泰制药有限公司 | 稳定的盐酸胺碘酮及其制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113072434B (zh) | 一种一步法制备环丙基甲基酮的方法 | |
CN114539193A (zh) | 一种盐酸胺碘酮中间体的制备方法 | |
CN114292256A (zh) | 一种适用于工业化生产的西瓜酮粗品制备方法及提纯方法 | |
CN113024396A (zh) | 一种奥司他韦的制备方法及其中间体 | |
CN116514800A (zh) | 盐酸戊乙奎醚的制备方法 | |
CN114671859B (zh) | 一种瑞舒伐他汀钙及其中间体的制备方法 | |
CN110698335A (zh) | 一种特布他林中间体的合成方法 | |
CN116199623A (zh) | 一种索托拉西布关键中间体的制备方法 | |
CN113943286B (zh) | 一种胆碱受体拮抗剂的制备方法 | |
CN114702425A (zh) | (s)-2-氨基-(s)-3-[吡咯烷酮-2’]丙氨酸衍生物及中间体的制备方法 | |
CN111100042B (zh) | 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法 | |
CN112047851B (zh) | 一种d-泛醇的制备方法 | |
CN105237346B (zh) | 手性α‑苯乙醇的优先结晶制备方法 | |
CN113651722A (zh) | 一种1-(3-羟基苯基)-1,3,3-三甲基脲的合成方法、中间体及其用途 | |
CN107021969A (zh) | 催化氧化制备生物素前体酮酸的方法 | |
CN105732613B (zh) | 一种9‑去甲基‑(+)‑α‑二氢丁苯那嗪的合成方法 | |
CN114349635B (zh) | 一种度鲁特韦核心中间体的合成方法 | |
CN113801089B (zh) | 一种克立硼罗中间体的制备方法 | |
CN107698582A (zh) | 一种丁苯那嗪及其中间体的合成方法 | |
CN113372273B (zh) | 一种伊伐布雷定中间体化合物iv | |
CN115850220B (zh) | 稳定的盐酸胺碘酮及其制备方法和用途 | |
CN113354659B (zh) | 甲磺酸艾日布林的合成 | |
CN106478555A (zh) | 一种紫杉烷类化合物及其制备方法 | |
CN114057695A (zh) | 一种阿美替尼关键中间体的合成方法和应用 | |
CN115745930A (zh) | 一种丁苯酞的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240218 Address after: 246004 No. 58, xiahong Road, high tech Industrial Development Zone, Anqing City, Anhui Province Applicant after: Anhui Puli Pharmaceutical Co.,Ltd. Country or region after: China Address before: 571127 Guilin Ocean Economic Development Zone, Meilan District, Haikou City, Hainan Province Applicant before: HAINAN POLY PHARM. Co.,Ltd. Country or region before: China Applicant before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Applicant before: Anhui Puli Pharmaceutical Co.,Ltd. |
|
TA01 | Transfer of patent application right |